Can a team of doctors improve lung cancer care for seniors?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 60 to 90 years. 2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). 3. Clinical stage I-IV (according to the 9th edition of the IASLC TNM staging system). 4. ECOG Performance Status 0-2. 5. Estimated life expectancy ≥ 3 months. 6. Able to tolerate baseline examinations (including CT, MRI, pulmonary function tests) and at least one planned treatment modality (surgery, ablation, SBRT, etc.) as assessed by the investigator. 7. Patients or their legal representatives provide written informed consent and commit to completing the full follow-up schedule (including questionnaires and functional assessments). 8. Other conditions deemed suitable by the investigator. Exclusion Criteria: 1. History of another active primary malignancy within the previous 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ, or another malignancy considered unlikely to affect the study outcomes. 2. Lung cancer cannot be confirmed by histologic or cytologic examination. 3. A medical emergency requiring immediate treatment that precludes completion of the baseline study procedures and MDT review before treatment initiation. 4. Cognitive or communication impairment that prevents completion of the core study procedures when no legally authorized representative or appropriate proxy assistance is available. 5. A contraindication to all clinically acceptable methods required for the core study-specific baseline assessment, with no suitable alternative assessment available. 6. Concurrent participation in another interventional study that mandates a treatment strategy incompatible with the CGA-informed MDT care pathway. 7. Any condition that makes the study-specific assessment procedures unsafe, provided that the reason for exclusion is documented by the investigator.